Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objectives of this Post Marketing Surveillance (PMS) are:
- Evaluation of the treatment effect of pramipexole on Restless Legs Syndrome (RLS)
severity as measured by International Restless Legs Syndrome Scale (IRLS) and Clinical
Global Impression Improvement scale (CGI- I)
- Evaluation of the time to reaching maintenance dose of pramipexole
- Evaluation of work productivity impairment associated with RLS based on the Work
Productivity and Activity Impairment Questionnaire (WPAI) questionnaire